文献速递骨软组织肉瘤与黑色素瘤

恩考芬尼联合比美替尼及帕博利珠单抗三药方案治疗晚期BRAFV600突变黑色素瘤的I期安全性结果

Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial.
PubMed 文献 · Eur J Cancer · 2021-10-13

IMMU-TARGET研究是一项开放标签I/II期试验,评估帕博利珠单抗、恩考芬尼和比美替尼三药联合治疗晚期BRAFV600突变黑色素瘤的安全性。I期部分采用3+3设计,15例患者入组,87%发生治疗相关不良事件,53%发生≥III级事件,未出现治疗相关死亡。14例可评估疗效患者总缓解率为64%(95%CI 35-87),中位随访25个月时12个月无进展生存率为41%(95%CI 13-68)。

要点

  • 三药联合方案在晚期BRAFV600突变黑色素瘤中可行且安全,未出现治疗相关死亡。
  • 常见III-IV级治疗相关不良事件为AST/GGT升高(6/15)和CPK升高(4/15)。
  • 14例可评估患者总缓解率64%,12个月无进展生存率41%。

核心结论

  • 帕博利珠单抗、恩考芬尼和比美替尼三药联合方案在晚期BRAFV600突变黑色素瘤中可行且安全,并带来有临床意义的疾病控制。

研究设计与样本

  • 开放标签I/II期IMMU-TARGET试验(NCT02902042),I期剂量探索部分采用3+3设计,共入组15例晚期BRAFV600突变黑色素瘤患者。

主要发现

  • 15例患者中13例(87%)发生治疗相关不良事件,8例(53%)发生≥III级治疗相关不良事件,无治疗相关死亡。
  • 最常见的III-IV级治疗相关不良事件为天冬氨酸转氨酶升高、γ-谷氨酰转移酶升高(6/15例)和肌酸磷酸激酶升高(4/15例)。
  • 14例可评估疗效患者的总缓解率为64%(95%CI 35-87)。
  • 中位随访25个月(IQR 9-28)时,12个月无进展生存率为41%(95%CI 13-68)。
  • 患者接受三药联合治疗的中位持续时间为24周(IQR 12-45)。

关键数值与推荐

  • 剂量水平0(DL0)为帕博利珠单抗200 mg每3周、恩考芬尼450 mg每日一次、比美替尼45 mg每日两次。
  • 预设减量方案:DL-1为恩考芬尼300 mg每日一次和比美替尼30 mg每日两次;DL-2为恩考芬尼200 mg每日一次和比美替尼30 mg每日两次。
  • DL0发生剂量限制性毒性:肌酸磷酸激酶升高伴细胞因子释放综合征(n=1)和γ-谷氨酰转移酶升高(n=1)。
  • DL-1后续3+3患者中未观察到剂量限制性毒性;DL0额外入组6例患者未发生剂量限制性毒性。

临床怎么用

  • 该三药联合方案可作为晚期BRAFV600突变黑色素瘤的可行治疗选择,但需密切监测肝功能、肌酸磷酸激酶及细胞因子释放综合征等不良事件。
  • 临床应用中应关注≥III级治疗相关不良事件,尤其是AST/GGT升高和CPK升高,必要时按预设方案调整恩考芬尼和比美替尼剂量。

局限性

  • 本研究为I期剂量探索部分,样本量较小(15例),安全性及疗效结果需进一步验证。
  • 研究因申办方决定在I期部分后终止,未继续进入II期,因该联合方案的临床疗效正在III期STARBOARD试验中评估。
  • 疗效数据基于14例可评估患者,置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination of immune checkpoint inhibitors and mitogen-activated protein kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-tumour responses induced by MAPKi. Here, we present phase I safety results from an open-label, phase I/II study of pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) triplet therapy in advanced, B-Raf proto-oncogene serine/threonine kinase (BRAF)V600-mutated melanoma (IMMU-TARGET, NCT02902042). METHODS: The dose finding phase I part used a 3 + 3 design, starting with the approved doses of PEM (200 mg every three weeks), ENC (450 mg once daily [QD]) and BIN (45 mg twice daily [BID]) as dose level (DL) 0. Reduction of the ENC and BIN doses (300 mg QD and 30 mg BID at DL-1 and 200 mg QD and 30 mg BID at DL-2) was preplanned in case of ≥2 dose-limiting toxicities (DLTs). Primary objectives were to estimate the recommended phase II dose of the triplet combination, DLT and safety. As per the sponsor's decision, the study was terminated after the phase I part, as the clinical efficacy of the combination is currently being investigated in a pivotal, placebo-controlled (PEM mono), double-blinded phase III trial (STARBOARD,NCT04657991). RESULTS: Fifteen patients were enrolled. DLTs of DL0 were creatine phosphokinase (CPK) elevation plus cytokine release syndrome (n = 1) and gamma glutamyl transferase (GGT) increase (n = 1). No DLT was observed in further 3 + 3 patients at DL-1. One (isolated GGT elevations) DLT of DL0 was questionable, as the patient had further episodes of isolated GGT elevations after treatment discontinuation. Hence, further 6 patients were enrolled at DL0: here, no DLT occurred. In total, 13 of 15 patients (87%) experienced a treatment-related adverse event (TRAE) and 8 patients (53%), a grade ≥III TRAE; there were no TRAE-related deaths. Increases in aspartate aminotransferases, GGT (6/15 patients) and CPK elevations (4/15) were the most common grade III-IV TRAE. In median, patients received triplet therapy for 24 weeks (interquartile range [IQR], 12-45). Of the 14 patients evaluable for efficacy, the overall response rate was 64% (95% confidence interval [CI], 35-87). At a median follow-up of 25 months (IQR, 9-28), progression-free survival at 12 months was 41% (95% CI, 13-68). CONCLUSIONS: Triplet therapy with PEM, ENC and BIN as used in the study was feasible and safe and led to clinically meaningful disease control.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zimmer L, Livingstone E, Krackhardt A, et al. Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. Eur J Cancer. 2021. PMID: 34655839. doi:10.1016/j.ejca.2021.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。